Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.

Abstract: An example device may include one or more processors to receive a request for a service from a requestor user device; provide transaction information associated with the service to a provider user device, where the transaction information may include location information corresponding to a location at which the service may be provided; obtain verification information from the requestor user device based on an interaction associated with the requestor user device or the provider user device at the location, where the verification information may include one or more characteristics of the requestor user device; generate a verification token based on the one or more characteristics of the requestor user device; and provide the verification information to the provider user device to permit the provider user device to verify the requestor user device, based on receiving the verification information and obtaining the verification token from the requestor user device.

Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.

Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.

Abstract: Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.

Abstract: A telescoping greeting card having a plurality of pockets and/or panels that are connected in sequence and configured to slidably telescope between a closed position wherein each of the pockets and/or panels are contained within a main panel and an open position wherein each of the pockets and/or panels are extended in a longitudinal array. The greeting card additionally contains a switch and a sound module with at least one pre-recorded audio file that may be played back upon removal of one of the panels or pockets of the greeting card, which triggers the switch.

Abstract: A telescoping greeting card having a plurality of pockets and/or panels that arc connected in sequence and configured to slidably telescope between a closed position wherein each of the pockets and/or panels are contained within a main panel and an open position wherein each of the pockets and/or panels are extended in a longitudinal array. The greeting card additionally contains a switch and a sound module with at least one pre-recorded audio file that may be played back upon removal of one of the panels or pockets of the greeting card, which triggers the switch.

Abstract: An apparatus and method for informing a monitored internal system status of an electronic device using a screen saver program is disclosed. When the screen saver program is activated (704), a virtual analog clock (706, 106) having a time-varying visual attribute (108, 110, 112) is displayed. The time-varying visual attribute is varied to indicate the status of the monitored internal system status during the time the screen saver program is active.